4Dx Successfully Raises $4M and Aims for Major Milestones in 2017

4DX are pleased to provide you with the latest update on the company’s journey. The company had a promising finale to 2016 and “looks set” for another great year ahead.

KEY TAKEAWAYS:

• 4Dx successfully hit its target of raising A$4 million last year, with the final details of the capital raising to be released in the coming weeks;
• Prominent oncologist Dr Robert A. Figlin has been appointed to our Board of Directors;
• Chairman and CEO, Andreas Fouras, has been invited to present the company’s preliminary clinical validation at The 2017 International Workshop on Pulmonary Imaging, on the 2^nd March 2017;
• The company is hoping to hit some major milestones in 2017, progress is continuing strongly towards the company’s first FDA application.

4Dx Limited is a medical technology start-up based in Melbourne, Australia, formed to commercialise four-dimensional lung imaging technology, conceived by 4Dx founder Andreas Fouras and initially developed by his research group at Monash University.

4Dx’s core technology, 4DxV, maps the breathing lungs using four dimensional X-ray technology, providing richer functional information, at earlier stages, when intervention is most effective. This proven and patented technology is quantitative, low dose and non-invasive. 4Dx is targeting its technology towards the diagnosis and monitoring of major respiratory conditions, including asthma, COPD and cystic fibrosis.

“4Dx is pleased to announce that due to an overwhelming response, the company’s $4 million Series A capital raise closed oversubscribed on 9th December, 2016.

Chairman and CEO Andreas Fouras says, “the domestic investment community has demonstrated a deep understanding of our proposition, and the value inherent in it.  We believe this result indicates a very clear acceptance of the need for 21st century diagnostic technology in the medical marketplace”.

The capital raise places a valuation of $36 million on 4Dx Limited.  Funds from the Series A investment round will be used to take the company’s first software product to market, including clinical studies to further validate the product, as well as the development and submission of its first application for US Food and Drug Administration (FDA) clearance.”

Request Offer